Pharma

Sun Pharma

What’s new (today): In buy calls for Monday; sector also watched after recent USFDA enforcement actions affecting a few peers last week. Why it matters: US generics pricing and compliance track record drive earnings more than short-term news. Beginner takeaway: Read USFDA status (warning letters, OAI/Voluntary Action), specialty portfolio progress, and R&D spend—key for resilience.